Intravenous immunoglobulin (IVIG) plus ciclosporin reduced the incidence of coronary artery abnormalities compared with IVIG alone (95% CI 0.25–0.86; P = 0.010) in a phase III study of 173 children with Kawasaki disease who were predicted to be unlikely to respond to IVIG therapy. Responsiveness to IVIG therapy was predicted on the basis of a composite risk score and individuals with pre-existing coronary artery abnormalities were excluded from the study. IVIG plus ciclosporin was safe and effective at 12 weeks, and no differences in adverse events were reported between treatment groups.
References
Original article
Hamada, H. et al. Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial. The Lancet 393, 1128–1137 (2019)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Collison, J. IVIG and ciclosporin for Kawasaki disease. Nat Rev Rheumatol 15, 250 (2019). https://doi.org/10.1038/s41584-019-0207-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-019-0207-9